Enterome, a Paris-based clinical-stage company, raised $19M in funding. The company intends to use the funds to advance its Phase 1/2 trial of EO2463 OncoMimics. This treatment targets multiple forms of indolent non-Hodgkin lymphoma. Led by CEO Pierre Bélichard, Enterome focuses on innovative immunotherapies for cancer.

Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body.


https://www.enterome.com/

Therapeutics

Enterome raises $19M in funding to advance its Phase 1/2 trial of EO2463 OncoMimics for treating indolent non-Hodgkin lymphoma.

Description

Company Information

Related People

Funding Insights

Enterome raises $19M in funding to advance its Phase 1/2 trial of EO2463 OncoMimics for treating indolent non-Hodgkin lymphoma.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information